Although Th2-targeted therapy—the IL-4 receptor antibody dupilumab that blocks both IL-4 and IL-13 signaling has achieved tremendous progress in specific populations (Langan et al., 2020), it clears only approximately one-third of patients, so, additional targeted therapies are required to resolve all subtypes of AD (Ungar et al., 2021). Here, IL13 is linked to Alzheimer disease.